VIRMA and prostate carcinoma: Moreover, VIRMA downregulation attenuated the aggressive phenotype of prostate cancer cells by reducing the stability and abundance of oncogenic lncRNAs through an overall reduction in m6A levels (Barros-Silva et al. 2020).